Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus

References

• Tanaka Y. State-of-The-art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020;23(4):465–471. doi:10.1111/1756-185X.13817
   PubMed Web of Science ®Google Scholar
• Gupta S, Kaplan MJ. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131(3):e144918. doi:10.1172/JCI144918
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18(3):133–145. doi:10.1038/s41584-021-00726-8
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, Phase 2 trial. Lancet. 2018;392(10143):222–231. doi:10.1016/S0140-6736(18)31363-1
   PubMed Web of Science ®Google Scholar
• Yurkovich M, Vostretsova K, Chen W, et al. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res. 2014;66(4):608–616. doi:10.1002/acr.22173
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii111–5. doi:10.1136/annrheumdis-2012-202576
   PubMedGoogle Scholar
• Wenzel J, van Holt N, Maier J, et al. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. J Invest Dermatol. 2016;136(6):1281–1283. doi:10.1016/j.jid.2016.02.015
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690550). J Immunol. 2011;186(7):4234–4243. doi:10.4049/jimmunol.1003668
   PubMed Web of Science ®Google Scholar
• Okiyama N, Furumoto Y, Villarroel VA, et al. Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib. J Invest Dermatol. 2014;134(4):992–1000. doi:10.1038/jid.2013.476
   PubMed Web of Science ®Google Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049. doi:10.1038/nm.3645
   PubMed Web of Science ®Google Scholar
• Chang Z, Wang Y, Zhou X, et al. STAT3 roles in viral infection: antiviral or proviral? Future Virol. 2018;13(8):557–574. doi:10.2217/fvl-2018-0033
   PubMedGoogle Scholar
• Darnell JE. STATs and gene regulation. Science. 1997;277(5332):1630–1635. doi:10.1126/science.277.5332.1630
   PubMed Web of Science ®Google Scholar
• Kotyla PJ, Engelmann M, Giemza-Stokłosa J, et al. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: does the Inhibitor Specificity Play a Role? Int J Mol Sci. 2021;22(5):2449. doi:10.3390/ijms22052449
   PubMed Web of Science ®Google Scholar
• Gao Q, Liang X, Shaikh AS, et al. JAK/STAT Signal Transduction: promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases. Curr Drug Targets. 2018;19(5):487–500. doi:10.2174/1389450117666161207163054
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Zarrin AA, Bao K, Lupardus P, et al. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20(1):39–63. doi:10.1038/s41573-020-0082-8
   PubMed Web of Science ®Google Scholar
• Waickman AT, Park JY, Park JH. The common γ-chain cytokine receptor: tricks-and-treats for T cells. Cell Mol Life Sci. 2016;73(2):253–269. doi:10.1007/s00018-015-2062-4
   PubMed Web of Science ®Google Scholar
• Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2019;58(6):953–962. doi:10.1093/rheumatology/key339
   PubMed Web of Science ®Google Scholar
• Gadina M, Chisolm DA, Philips RL, et al. Translating JAKs to Jakinibs. J Immunol. 2020;204(8):2011–2020. doi:10.4049/jimmunol.1901477
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Tanaka Y. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update. Expert Rev Clin Immunol. 2019;15(7):693–700. doi:10.1080/1744666X.2019.1608821
   PubMed Web of Science ®Google Scholar
• Hagberg N, Joelsson M, Leonard D, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis. 2018;77(7):1070–1077. doi:10.1136/annrheumdis-2017-212794
   PubMed Web of Science ®Google Scholar
• You H, Xu D, Zhao J, et al. JAK Inhibitors: prospects in Connective Tissue Diseases. Clin Rev Allergy Immunol. 2020;59(3):334–351. doi:10.1007/s12016-020-08786-6
   PubMed Web of Science ®Google Scholar
• Montero P, Milara J, Roger I, et al. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci. 2021;22(12):6211
   PubMed Web of Science ®Google Scholar
• Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023–5038. doi:10.1021/jm401490p
   PubMed Web of Science ®Google Scholar
• Al Khalili A, Dutz JP. Janus Kinase Inhibition and SLE: is this a Plausible Treatment Option for SLE? Curr Treat Options Rheumatol. 2020;6:406–417. doi:10.1007/s40674-020-00155-w
   Google Scholar
• Gadina M, Johnson C, Schwartz D, et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J Leukoc Biol. 2018;104(3):499–514. doi:10.1002/JLB.5RI0218-084R
   PubMed Web of Science ®Google Scholar
• de la Varga Martínez R, Rodríguez-Bayona B, Añez GA, et al. Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation. Eur J Immunol. 2017;47(7):1211–1219. doi:10.1002/eji.201646872
   PubMed Web of Science ®Google Scholar
• Alunno A, Padjen I, Fanouriakis A, et al. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent. Cells. 2019;8(8):898. doi:10.3390/cells8080898
   PubMed Web of Science ®Google Scholar
• Lee J, Park Y, Jang SG, et al. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus. Front Immunol. 2021;12:704526. doi:10.3389/fimmu.2021.704526
   PubMedGoogle Scholar
• Yan Q, Chen W, Song H, et al. Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor. Front Immunol. 2021;12:675542. doi:10.3389/fimmu.2021.675542
   PubMedGoogle Scholar
• È R, de Ramon L, Draibe Bordignon J, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18(1):134. doi:10.1186/s13075-016-1034-x
   PubMedGoogle Scholar
• Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18(1):41. doi:10.1186/s12865-017-0225-9
   PubMedGoogle Scholar
• Fetter T, Smith P, Guel T, et al. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Front Immunol. 2020;11:344. doi:10.3389/fimmu.2020.00344
   PubMed Web of Science ®Google Scholar
• Chan ES, Herlitz LC, Jabbari A. Ruxolitinib Attenuates Cutaneous Lupus Development in a Mouse Lupus Model. J Invest Dermatol. 2015;135(7):1912–1915. doi:10.1038/jid.2015.107
   PubMed Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12(1):3391. doi:10.1038/s41467-021-23361-z
   PubMed Web of Science ®Google Scholar
• Richter P, Cardoneanu A, Burlui AM, et al. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus? Int J Mol Sci. 2022;23(19):11788. doi:10.3390/ijms231911788
   PubMedGoogle Scholar
• Shi H, Gudjonsson JE, Kahlenberg JM. Treatment of cutaneous lupus erythematosus: current approaches and future strategies. Curr Opin Rheumatol. 2020;32(3):208–214. doi:10.1097/BOR.0000000000000704
   PubMed Web of Science ®Google Scholar
• Garufi C, Mancuso S, Spinelli FR, et al. Janus kinases inhibitors for treating patients with rhupus. Joint Bone Spine. 2020;87(6):673–674. doi:10.1016/j.jbspin.2020.05.010
   PubMedGoogle Scholar
• Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep. 2022;28:133–135. doi:10.1016/j.jdcr.2022.08.038
   PubMedGoogle Scholar
• You H, Zhang G, Wang Q, et al. Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis. 2019;78(10):1441–1443. doi:10.1136/annrheumdis-2019-215455
   PubMed Web of Science ®Google Scholar
• Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep. 2021;20:61–64. doi:10.1016/j.jdcr.2021.09.030
   PubMedGoogle Scholar
• Zimmermann N, Wolf C, Schwenke R, et al. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation. JAMA Dermatol. 2019;155(3):342–346. doi:10.1001/jamadermatol.2018.5077
   PubMed Web of Science ®Google Scholar
• Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus. Available from: https://clinicaltrials.gov/ct2/show/NCT05048238. Accessed February 8, 2023.
   Google Scholar
• Use of Baricitenib to Maintain of Remission. Available from: https://clinicaltrials.gov/ct2/show/NCT05686746. Accessed February 8,2023.
   Google Scholar
• Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus; Available from: https://clinicaltrials.gov/ct2/show/NCT04908280. Accessed February 8, 2023.
   Google Scholar